JAMA Netw Open
Statins linked to better survival in hormone receptor–positive breast cancer
Clinical takeaway: Statins should not be started solely to improve breast cancer outcomes, but this study suggests that postdiagnostic statin use may be associated with better survival in early hormone receptor–positive disease. For patients who already need statins for cardiovascular risk reduction, the findings add to the rationale for continuing therapy while prospective confirmation is awaited.
Statins are commonly prescribed for cardiovascular prevention, and interest in their potential anticancer effects has persisted for years. New registry data from Finland suggest that any survival association may depend on breast cancer subtype, with the strongest signal seen after diagnosis in hormone receptor–positive tumors.
In this retrospective population-based cohort of 7,389 women with early breast cancer, prediagnostic statin use was not associated with improved breast cancer–specific or all-cause survival. Postdiagnostic statin use, however, was associated with lower breast cancer–specific mortality and lower all-cause mortality in the overall cohort.
The benefit appeared concentrated in hormone receptor–positive disease. Statin use after diagnosis was associated with better breast cancer–specific survival in luminal A-like, luminal B-like (HER2-negative), and luminal B-like (HER2-positive) subtypes. In contrast, no clear survival benefit was seen in HER2-positive nonluminal or triple-negative disease.
The association also appeared dose-related for breast cancer–specific mortality, with higher statin use linked to greater risk reduction in the overall cohort. Importantly, the findings were not meaningfully changed after adjustment for postdiagnosis cholesterol levels, suggesting the association may not be explained by lipid lowering alone.
For clinicians, the study does not establish statins as cancer therapy, but it may be reassuring for patients already taking statins for cardiovascular indications and may help inform future trials focused on hormone receptor–positive breast cancer.
“In this cohort study of patients with early breast cancer, postdiagnostic statin use was associated with lower all-cause and breast cancer–specific mortality among patients with hormone receptor–positive intrinsic subtypes,” said the study authors. “These findings suggest that statin therapy may improve survival of patients with early hormone receptor–positive subtypes.”
Source: Palmi S, et al. (2026, June 2). JAMA Netw Open. Statin use and survival in early breast cancer according to different intrinsic subtypes